BioDrugs

, Volume 19, Issue 5, pp 323–325

Spotlight on Subcutaneous Recombinant Interferon-β-1a (Rebif®) in Relapsing-Remitting Multiple Sclerosis

Authors

  • David Murdoch
    • Adis International Limited
    • Adis International Limited
Adis Spotlight

DOI: 10.2165/00063030-200519050-00005

Cite this article as:
Murdoch, D. & Lyseng-Williamson, K.A. BioDrugs (2005) 19: 323. doi:10.2165/00063030-200519050-00005

Abstract

Subcutaneous recombinant interferon-β-1a (Rebif®) 22 or 44μg three times weekly is a valuable option in the first-line treatment in patients with relapsing-remitting multiple sclerosis. It has shown benefits on outcome measures related to relapses, progression of disability, and magnetic resonance imaging in clinical trials. A significant efficacy advantage for subcutaneous interferon-β-1a three times weekly over intramuscular interferon-β-1a 30μg once weekly was shown at 24 and 48 weeks. The most common adverse events are generally mild and clinically manageable. Considering both direct and indirect comparative clinical trial data, an assessment suggests that subcutaneous interferon-β-1a 44μg three times weekly has the best benefit-to-risk values of the available disease-modifying drugs used to treat relapsing-remitting multiple sclerosis. 1 This Spotlight is derived from abstract and summary text of an Adis Drug Evaluation originally published in full in Drugs 2005; 65 (9): 1295-312. Reviewers of the original full text article are listed in the Acknowledgments section. 2 The use of trade names is for product identification purposes only and does not imply endorsement.

Copyright information

© Adis Data Information BV 2005